Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + Carboplatin vs Paclitaxel + Epirubicin in MBC
NCT02207361Phase 4Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2013
- Primary completion
- Nov 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised trial of carboplatin in breast cancer (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression Free Survival. Status: unknown.
02
Drugs
carboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02207361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207361.